Alterome Therapeutics raises $132M Series B led by Goldman Sachs Alternatives for two precision oncology programs.
Alterome Therapeutics, a cancer-focused biopharmaceutical company, has raised $132M in Series B funding led by Goldman Sachs Alternatives. The funds will support the advancement of two precision oncology programs into clinical development within 12 months. Participants in the round included Canaan Partners, Driehaus Capital Management, Invus, Digitalis Ventures, Blue Owl Capital, and existing investors.
April 03, 2024
5 Articles